FOXO4-DRI (10mg)

FOXO4-DRI, or Proxofim, is a lab-engineered retro-inverso peptide based on a FOXO4 protein fragment. Its reversed D-amino acid structure boosts durability against breakdown, allowing extended activity in models. It disrupts FOXO4-p53 interactions in aging cells, prompting selective self-destruction of dysfunctional "senescent" cells while sparing normal ones.

Built with mirrored, reversed amino acids, FOXO4-DRI resists enzymatic degradation for prolonged effects. It targets the FOXO4-p53 binding in senescent cell nuclei, freeing p53 to relocate to mitochondria and trigger apoptosis specifically in those impaired cells, bypassing healthy tissue.

Preclinical animal trials reveal reduced senescent cell loads, enhanced organ function, hormonal equilibrium, and diminished fibrosis in aged subjects. It also curbs pro-inflammatory SASP factors, fostering better tissue environments. Experimental setups often use brief, intermittent subcutaneous dosing cycles to maximize senolytic impact without buildup. For research, mix the 10 mg vial with 3 ml bacteriostatic water for ~3.33 mg/mL (1 unit ≈ 33.3 mcg on U-100 syringes). Standard investigative doses hover around 300–500 mcg daily during active periods.